-
公开(公告)号：US10221242B2
公开(公告)日：2019-03-05
申请号：US15402807
申请日：2017-01-10
Applicant: PFIZER INC.
Inventor： Oi Kwan Wong , Joyce Ching Chou , Barbra Johnson Sasu
IPC: A61K39/395 , C07K16/28 , C07K16/30 , A61K39/00
Abstract: The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.
-
公开(公告)号：US20230002498A1
公开(公告)日：2023-01-05
申请号：US17830324
申请日：2022-06-01
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
公开(公告)号：US11279764B2
公开(公告)日：2022-03-22
申请号：US16163243
申请日：2018-10-17
Applicant: Pfizer Inc.
Inventor： Oi Kwan Wong , Joyce Ching Chou , Barbra Johnson Sasu
Abstract: The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.
-
公开(公告)号：US10259876B2
公开(公告)日：2019-04-16
申请号：US15402760
申请日：2017-01-10
Applicant: PFIZER INC.
Inventor： Oi Kwan Wong , Joyce Ching Chou , Mathilde Brunnhilde Dusseaux , Julianne Smith , Barbra Johnson Sasu
IPC: A61K35/17 , C12N9/64 , A61K31/436 , C12N15/62 , C07K16/28 , C07K14/725 , C07K14/47 , A61K39/00 , A61K38/00
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
-
公开(公告)号：US11673953B2
公开(公告)日：2023-06-13
申请号：US16802822
申请日：2020-02-27
Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
Inventor： Yi Zhang , Thomas John Van Blarcom , Siler Panowski , Silvia K. Tacheva-Grigorova , Barbra Johnson Sasu
CPC classification number: C07K16/2809 , A61P35/00 , C07K16/2887 , C12N15/63 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2319/70
Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
-
Patent Agency Ranking
公开(公告)号：US20220227874A1
公开(公告)日：2022-07-21
申请号：US17586321
申请日：2022-01-27
Applicant: Pfizer Inc.
Inventor： Oi Kwan Wong , Joyce Ching Chou , Mathilde Brunnhilde Dusseaux , Julianne Smith , Barbra Johnson Sasu
IPC: C07K16/28 , C07K14/47 , C07K14/725
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
-
公开(公告)号：US11267892B2
公开(公告)日：2022-03-08
申请号：US16255348
申请日：2019-01-23
Applicant: Pfizer Inc.
Inventor： Oi Kwan Wong , Joyce Ching Chou , Mathilde Brunnhilde Dusseaux , Julianne Smith , Barbra Johnson Sasu
IPC: A61K35/17 , C12N9/64 , A61K31/436 , C07K16/28 , C07K14/47 , C07K14/725 , A61K38/00 , A61K39/00
Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.
-
公开(公告)号：US20190233529A1
公开(公告)日：2019-08-01
申请号：US16264485
申请日：2019-01-31
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
CPC classification number: C07K16/2875 , A61K2039/505 , A61P35/00 , C07K16/2809 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
公开(公告)号：US10294304B2
公开(公告)日：2019-05-21
申请号：US15085317
申请日：2016-03-30
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien Kuo , Bijan Andre Boldajipour , Javier Fernando Chaparro Riggers , Philippe Duchateau , Roman Galetto , Alexandre Juillerat , Thomas Charles Pertel , Arvind Rajpal , Barbra Johnson Sasu , Cesar Adolfo Sommer , Julien Valton , Thomas John Van Blarcom
IPC: C07K16/28 , A61K39/395 , C12N15/63 , C07K14/725 , C07K14/705 , A61K39/00 , A61K31/7076 , A61K35/17 , A61K38/00
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
-
公开(公告)号：US11987634B2
公开(公告)日：2024-05-21
申请号：US17830324
申请日：2022-06-01
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
CPC classification number: C07K16/2875 , A61P35/00 , C07K16/2809 , A61K2039/505 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.024 seconds)
